{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:36:36Z","timestamp":1773272196036,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,12,23]],"date-time":"2014-12-23T00:00:00Z","timestamp":1419292800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1038\/nrendo.2014.227","type":"journal-article","created":{"date-parts":[[2014,12,23]],"date-time":"2014-12-23T07:54:53Z","timestamp":1419321293000},"page":"73-74","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Advances in therapy of adenomas secreting GH, ACTH and TSH"],"prefix":"10.1038","volume":"11","author":[{"given":"Annamaria","family":"Colao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,23]]},"reference":[{"key":"BFnrendo2014227_CR1","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nrendo.2014.21","volume":"10","author":"A Giustina","year":"2014","unstructured":"Giustina, A.  et al. Expert consensus document: a consensus on the medical treatment of acromegaly. Nat. Rev. Endocrinol. 10, 243\u2013248 (2014).","journal-title":"Nat. Rev. Endocrinol."},{"key":"BFnrendo2014227_CR2","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1210\/jc.2003-031052","volume":"89","author":"J van der Hoek","year":"2004","unstructured":"van der Hoek, J.  et al. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J. Clin. Endocrinol. Metab. 89, 638\u2013645 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2014227_CR3","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1210\/jc.2013-2480","volume":"99","author":"A Colao","year":"2014","unstructured":"Colao, A.  et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J. Clin. Endocrinol. Metab. 99, 791\u2013799 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2014227_CR4","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1210\/jc.2013-1771","volume":"98","author":"RR Henry","year":"2013","unstructured":"Henry, R. R.  et al. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J. Clin. Endocrinol. Metab. 98, 3446\u20133453 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2014227_CR5","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1016\/S0140-6736(06)68699-6","volume":"367","author":"J Newell-Price","year":"2006","unstructured":"Newell-Price, J.  et al. Cushing's syndrome. Lancet 367, 1605\u20131617 (2006).","journal-title":"Lancet"},{"key":"BFnrendo2014227_CR6","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/cen.12431","volume":"81","author":"R Pivonello","year":"2014","unstructured":"Pivonello, R.  et al. Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a phase III study. Clin. Endocrinol. (Oxf.) 81, 408\u2013417 (2014).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo2014227_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/cen.12259","volume":"80","author":"S Petersenn","year":"2014","unstructured":"Petersenn, S.  et al. High variability in baseline urinary free cortisol values in patients with Cushing's disease. Clin. Endocrinol. (Oxf.) 80, 261\u2013269 (2014).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo2014227_CR8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000351007","volume":"2","author":"P Beck-Peccoz","year":"2013","unstructured":"Beck-Peccoz, P., Lania, A., Beckers, A., Chatterjee, K. & Wemeau, J. L. 2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Eur. Thyroid J. 2, 76\u201382 (2013).","journal-title":"Eur. Thyroid J."},{"key":"BFnrendo2014227_CR9","doi-asserted-by":"publisher","unstructured":"Gatto, F.  et al. Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: might somatostatin analogs have a role as first-line therapy? Pituitary \n                    http:\/\/dx.doi.org\/10.1007\/s11102-014-0611\u20138\n                    \n                  .","DOI":"10.1007\/s11102-014-0611-8"},{"key":"BFnrendo2014227_CR10","first-page":"1","volume":"19","author":"S Yamada","year":"2014","unstructured":"Yamada, S.  et al. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases. J. Neurosurg. 19, 1\u201312 (2014).","journal-title":"J. Neurosurg."}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2014.227.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2014.227","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2014.227.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:44:17Z","timestamp":1684467857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrendo.2014.227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,23]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["BFnrendo2014227"],"URL":"https:\/\/doi.org\/10.1038\/nrendo.2014.227","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,23]]},"assertion":[{"value":"23 December 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author has received speaker honoraria and consultancy fees from Novartis in relation to the development of pasireotide for acromegaly.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}